SU2C Catalyst is an unique collaborative initiative intended to leverage all stages of the pharmaceutical, biotechnology, diagnostic, and devices industries to bring new treatments to patients as rapidly as possible. These SU2C Catalyst Team Grants facilitate the collaboration between industry and academic scientists in the cancer community who will conduct collaborative research projects that will deliver significant benefits for patients and society, accelerating the development of new treatments and, where appropriate, combination therapies.

Meet the active SU2C Catalyst® Teams

• SU2C Catalyst® Sarcoma Team: Pembrolizumab and radiation therapy to improve outcome in high-risk sarcoma
• SU2C Catalyst® Neoadjuvant Melanoma Team: Neoadjuvant Therapy for Patients with High-Risk Stage III
• SU2C Catalyst® Triple-Negative Breast Cancer Team: Combination Ipatasertib and Atezolizumab to Prevent Recurrence in TNBC. 
• SU2C Catalyst® Prostate Cancer Team: Atezolizumab, Abiraterone, and SBRT in Hormone Sens M1b PCa

SU2C Catalyst® SARCOMA Team: Pembrolizumab and radiation therapy to improve outcome in high-risk sarcoma

Research

Patients with soft tissue sarcomas often develop metastasis in the lung, leading to death. Recent studies suggest that radiation therapy can act together with immune checkpoint inhibitors to attack cancer cells. The team led by Dr. Kirsch is conducting a trial to test whether combining pembrolizumab (immune checkpoint inhibitor) with radiation therapy before surgery can destroy small sarcoma deposits in the lungs.

SU2C CATALYST® NEOADJUVANT MELANOMA TEAM: NEOADJUVANT THERAPY FOR PATIENTS WITH HIGH-RISK STAGE III MELANOMA

SU2C CATALYST® TRIPLE-NEGATIVE BREAST CANCER TEAM: COMBINATION IPATASERTIB AND ATEZOLIZUMAB TO PREVENT RECURRENCE IN TNBC

SU2C CATALYST® PROSTATE CANCER TEAM: ATEZOLIZUMAB, ABIRATERONE, AND SBRT IN HORMONE SENS M1B PCA